{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:15:00Z","timestamp":1783430100323,"version":"3.54.6"},"reference-count":35,"publisher":"IMR Press","issue":"6","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LQ23H090019"],"award-info":[{"award-number":["LQ23H090019"]}]},{"name":"Traditional Chinese Medicine Science and Technology of Zhejiang Province","award":["2024ZL291"],"award-info":[{"award-number":["2024ZL291"]}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"crossref","award":["2022KY506"],"award-info":[{"award-number":["2022KY506"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"crossref","award":["2024KY025"],"award-info":[{"award-number":["2024KY025"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Neurol."],"abstract":"<jats:p>Background:Ocular myasthenia gravis (OMG) is an autoimmune disorder characterized by weakness of the extraocular muscles. This study was developed to investigate the relationship between immunotherapy efficacy and OMG generalization as a function of antibody status, and to explore the efficacy of different immunotherapies in preventing OMG generalization.Methods:This retrospective study included 60 patients admitted to our hospital with initial OMG who were followed for more than two years. Time to generalization was calculated from symptom onset. The proportional hazards assumption was tested using time-dependent covariates, employing Cox regression and Kaplan-Meier analyses to analyze associations for this patient cohort.Results:Among the 60 patients (28 converted OMG; 32 pure OMG), the median time to generalization was 52 months (interquartile range (IQR): 16\u2013117). Antibody positivity was an independent risk factor for generalization (hazard ratio (HR) = 3.89, 95% confidence interval [CI]: 1.26\u201312.01, p = 0.018). In antibody-positive patients, immunotherapy significantly reduced generalization risk (HR = 0.17, 95% CI: 0.04\u20130.62, p = 0.008). Conclusion:The time from OMG onset to generalization can be prolonged. While antibody positivity was independently associated with generalization risk in this study cohort, immunotherapy was linked to a time-stable reduction in this risk among antibody-positive patients. These findings provide a preliminary basis for antibody-status-based individualized treatment in OMG.<\/jats:p>","DOI":"10.31083\/rn50142","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:23:19Z","timestamp":1783426999000},"source":"Crossref","is-referenced-by-count":0,"title":["Association Between Immunotherapy and Generalization in Ocular Myasthenia Gravis as a Function of Antibody Status"],"prefix":"10.31083","volume":"81","author":[{"given":"Siyu","family":"Xie","sequence":"first","affiliation":[{"name":"The Second Clinical Medical College of Hangzhou Normal University, 310014 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Guo","sequence":"additional","affiliation":[{"name":"Center for Pain Management Department, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital, Hangzhou Medical College), 310014 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 310016 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Guo","sequence":"additional","affiliation":[{"name":"Center for Rehabilitation Medicine, Department of Neurology, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital, Hangzhou Medical College), 310014 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Cheng","sequence":"additional","affiliation":[{"name":"Center for Rehabilitation Medicine, Department of Neurology, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital, Hangzhou Medical College), 310014 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Song","sequence":"additional","affiliation":[{"name":"Center for Rehabilitation Medicine, Department of Neurology, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital, Hangzhou Medical College), 310014 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrong","family":"Li","sequence":"additional","affiliation":[{"name":"Center for Rehabilitation Medicine, Department of Neurology, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital, Hangzhou Medical College), 310014 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manman","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center for Rehabilitation Medicine, Department of Neurology, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital, Hangzhou Medical College), 310014 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8754-3677","authenticated-orcid":true,"given":"Yiqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Rehabilitation Medicine, Department of Neurology, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital, Hangzhou Medical College), 310014 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Oger J, Frykman H. An update on laboratory diagnosis in myasthenia gravis. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2015; 444: 126\u2013131.","DOI":"10.1016\/j.cca.2015.01.042"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016; 87: 419\u2013425.","DOI":"10.1212\/WNL.0000000000002790"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Bever CT Jr, Aquino AV, Penn AS, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Annals of Neurology. 1983; 14: 516\u2013519.","DOI":"10.1002\/ana.410140504"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. Journal of Neurology, Neurosurgery, and Psychiatry. 1997; 62: 156\u2013162.","DOI":"10.1136\/jnnp.62.2.156"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. Journal of Neurology, Neurosurgery, and Psychiatry. 1989; 52: 1121\u20131127.","DOI":"10.1136\/jnnp.52.10.1121"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE. EFNS\/ENS Guidelines for the treatment of ocular myasthenia. European Journal of Neurology. 2014; 21: 687\u2013693.","DOI":"10.1111\/ene.12359"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021; 96: 114\u2013122.","DOI":"10.1212\/WNL.0000000000011124"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Nall S, Majeed J, Ahmed Mohsen Alrashidi A, Alhneif M, Hannan Asghar A, Mubarik A, et al. Effectiveness of Immunosuppressive Therapy in Preventing the Progression of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis: A Systematic Review and Meta-Analysis. Cureus. 2025; 17: e80172.","DOI":"10.7759\/cureus.80172"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Bhanushali MJ, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology. 2008; 71: 1335\u20131341.","DOI":"10.1212\/01.wnl.0000327669.75695.38"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Li M, Ge F, Guo R, Ruan Z, Gao Y, Niu C, et al. Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis. Therapeutic Advances in Neurological Disorders. 2019; 12: 1756286419876521.","DOI":"10.1177\/1756286419876521"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Wong SH, Huda S, Vincent A, Plant GT. Ocular myasthenia gravis: controversies and updates. Current Neurology and Neuroscience Reports. 2014; 14: 421.","DOI":"10.1007\/s11910-013-0421-9"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Feng X, Huan X, Yan C, Song J, Lu J, Zhou L, et al. Adult Ocular Myasthenia Gravis Conversion: A Single-Center Retrospective Analysis in China. European Neurology. 2020; 83: 182\u2013188.","DOI":"10.1159\/000507853"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Li F, Hotter B, Swierzy M, Ismail M, Meisel A, R\u00fcckert JC. Generalization after ocular onset in myasthenia gravis: a case series in Germany. Journal of Neurology. 2018; 265: 2773\u20132782.","DOI":"10.1007\/s00415-018-9056-8"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Lee BJ, Park J, Ahn H, Lim HT. Analysis of clinical features and outcomes in patients with ocular myasthenia gravis according to anti-acetylcholine receptor antibody-seropositivity. Japanese Journal of Ophthalmology. 2024; 68: 681\u2013687.","DOI":"10.1007\/s10384-024-01125-8"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Menon D, Alharbi M, Katzberg HD, Bril V, Mendoza MG, Barnett-Tapia C. Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study. Neurology. 2024; 103: e209722.","DOI":"10.1212\/WNL.0000000000209722"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Mazzoli M, Ariatti A, Valzania F, Kaleci S, Tondelli M, Nichelli PF, et al. Factors affecting outcome in ocular myasthenia gravis. The International Journal of Neuroscience. 2018; 128: 15\u201324.","DOI":"10.1080\/00207454.2017.1344237"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology. 2009; 72: 1548\u20131554.","DOI":"10.1212\/WNL.0b013e3181a41211"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Teo KY, Tow SL, Haaland B, Gosavi TD, Jing-Liang L, Yew Long LO, et al. Low conversion rate of ocular to generalized myasthenia gravis in Singapore. Muscle & Nerve. 2018; 57: 756\u2013760.","DOI":"10.1002\/mus.25983"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Gui M, Luo X, Lin J, Li Y, Zhang M, Zhang X, et al. Long-term outcome of 424 childhood-onset myasthenia gravis patients. Journal of Neurology. 2015; 262: 823\u2013830.","DOI":"10.1007\/s00415-015-7638-2"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Heckmann JM, Europa TA, Soni AJ, Nel M. The Epidemiology and Phenotypes of Ocular Manifestations in Childhood and Juvenile Myasthenia Gravis: A Review. Frontiers in Neurology. 2022; 13: 834212.","DOI":"10.3389\/fneur.2022.834212"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Feng HY, Wang HY, Liu WB, He XT, Huang X, Luo CM, et al. The high frequency and clinical feature of seronegative myasthenia gravis in Southern China. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2013; 34: 919\u2013924.","DOI":"10.1007\/s10072-012-1159-x"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Gu\u00e9guen A, Hijazi B, Zuber K, Deschamps R, Lamirel C, Vignal-Clermont C, et al. Generalization of ocular myasthenia gravis 10 years after onset. Journal of Neurology. 2022; 269: 6597\u20136604.","DOI":"10.1007\/s00415-022-11316-3"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Kamarajah SK, Sadalage G, Palmer J, Carley H, Maddison P, Sivaguru A. Ocular presentation of myasthenia gravis: A natural history cohort. Muscle & Nerve. 2018; 57: 622\u2013627.","DOI":"10.1002\/mus.25971"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Wang LL, Zhang Y, He ML. Clinical Features and Prognosis of Ocular Myasthenia Gravis Patients with Different Phenotypes. Chinese Medical Journal. 2015; 128: 2682\u20132684.","DOI":"10.4103\/0366-6999.166032"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Gilbert ME, De Sousa EA, Savino PJ. Ocular Myasthenia Gravis treatment: the case against prednisone therapy and thymectomy. Archives of Neurology. 2007; 64: 1790\u20131792.","DOI":"10.1001\/archneur.64.12.1790"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. Journal of Neurology. 2009; 256: 1314\u20131320.","DOI":"10.1007\/s00415-009-5120-8"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. The New England Journal of Medicine. 2016; 375: 511\u2013522.","DOI":"10.1056\/NEJMoa1602489"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Guo RJ, Gao T, Ruan Z, Zhou HY, Gao F, Xu Q, et al. Risk Factors for Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort Study. Neurology and Therapy. 2022; 11: 73\u201386.","DOI":"10.1007\/s40120-021-00292-x"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Mee J, Paine M, Byrne E, King J, Reardon K, O'Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society. 2003; 23: 251\u2013255.","DOI":"10.1097\/00041327-200312000-00002"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Birmanns B, Brenner T, Abramsky O, Steiner I. Seronegative myasthenia gravis: clinical features, response to therapy and synthesis of acetylcholine receptor antibodies in vitro. Journal of the Neurological Sciences. 1991; 102: 184\u2013189.","DOI":"10.1016\/0022-510x(91)90067-h"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Di Stefano V, Iacono S, Militello M, Leone O, Rispoli MG, Ferri L, et al. Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2024; 45: 3481\u20133494.","DOI":"10.1007\/s10072-024-07368-0"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Duan W, Peng Y, Jin W, Ouyang S, Yang H. Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma Myasthenia Gravis. Journal of Immunology Research. 2021; 2021: 9138548.","DOI":"10.1155\/2021\/9138548"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Narayanaswami P, Sanders DB, Thomas L, Thibault D, Blevins J, Desai R, et al. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study. The Lancet. Neurology. 2024; 23: 267\u2013276.","DOI":"10.1016\/S1474-4422(24)00028-0"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Vinciguerra C, D'Amico A, Bevilacqua L, Rini N, D'Apolito M, Liberatoscioli E, et al. Effectiveness and Safety of Mycophenolate Mophetil in Myasthenia Gravis: A Real-Life Multicenter Experience. Brain Sciences. 2024; 14: 774.","DOI":"10.3390\/brainsci14080774"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Ma J, Chen D, Yi F, Song J, Luo S, Zhong H, et al. Optimal time for the addition of non-corticosteroid immunosuppressants in myasthenia gravis: a single-center retrospective study in China. Frontiers in Neurology. 2024; 15: 1474508.","DOI":"10.3389\/fneur.2024.1474508"}],"container-title":["Revista de Neurolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RN\/81\/6\/10.31083\/RN50142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:24:00Z","timestamp":1783427040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RN\/81\/6\/10.31083\/RN50142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"alternative-id":["S0210-0010(26)00124-6"],"URL":"https:\/\/doi.org\/10.31083\/rn50142","relation":{},"ISSN":["0210-0010","1576-6578"],"issn-type":[{"value":"0210-0010","type":"print"},{"value":"1576-6578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"50142"}}